FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?
Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.
Pharma & Biotech
Pharma & Biotech
ROSELLA trial at ASCO 2026: Corcept’s Lifyorli subgroup data and what it means for platinum-resistant ovarian cancer practice
Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.
Pharma & Biotech
AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy
Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.
Pharma & Biotech
Why Johnson & Johnson’s May 19 RBC fireside chat matters more than it first appears
Johnson & Johnson will join RBC Healthcare 2026 on May 19. Read why investors will watch the fireside chat for growth, guidance, and risk signals.
Pharma & Biotech
From embryo science to face cream, the AV Laboratories story is hard to ignore
Discover how AV Laboratories is using IVF-inspired biotech and molecular skincare science to reshape skin longevity. Read the full analysis now.
Pharma & Biotech
STK-012 shows promise in resistant lung cancer biology, but can Synthekine deliver in Phase 2?
Synthekine’s STK-012 showed encouraging AACR 2026 data in resistant NSCLC. Read what the results could mean for frontline lung cancer treatment.
Pharma & Biotech
Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?
Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.
Pharma & Biotech
FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.
Pharma & Biotech
Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate
Lantern Pharma’s LP-300 showed an early EGFR L858R lung cancer signal. Read what the FDA meeting and trial redesign could change next.
Medical Devices & Diagnostics
Can Hologic’s breast imaging AI close one of mammography’s most stubborn detection gaps?
Hologic’s latest breast imaging AI data suggests stronger detection of hard-to-find cancers. Read what it could mean for screening adoption.